Cacciola I, Russo G, Filomia R, et al. - Researchers conducted this prospective study to assess the impacts of anti-hepatitis C virus (HCV) direct-acting antiviral (DAA) treatments on long-term glucose control in HCV/type 2 diabetes mellitus (T2DM) patients with chronic hepatitis C (CHC) or with cirrhosis. One hundred eighty-two consecutive HCV/T2DM patients who achieved viral clearance with DAA treatment were included in the study. Clinical, biochemical and instrumental parameters were collected at baseline and at 48, 96 and 120 weeks (48w, 96w and 120w, respectively) after discontinuing DAA therapy. According to multivariate logistic regression analysis, patients with chronic hepatitis have a 2.5 times greater chance of improving their glycemic values than patients with liver cirrhosis. In HCV/diabetic patients with chronic hepatitis, DAA-based HCV cure results in a significant and long-lasting improvement in glycaemic control, whereas cirrhotic HCV/diabetic subjects only experience a transient benefit from virus elimination.